Harrow (HROW) Non Operating Investment Income (2017 - 2024)
Harrow's (HROW) quarterly Non Operating Investment Income came in at -$1.9 million in Q2 2024, down 169.33% year-on-year from $2.8 million in Q3 2023, and down 54.09% quarter-over-quarter from -$1.2 million in Q1 2024.
Harrow (HROW) Non Operating Investment Income (2017 - 2024) Analysis & Trends
Harrow's Non Operating Investment Income history runs 8 years deep, the most recent figure standing at -$1.9 million for Q2 2024.
- On a quarterly basis, Non Operating Investment Income fell 169.33% year-over-year to -$1.9 million in Q2 2024; TTM through Dec 2024 was -$3.2 million, a 202.55% decrease from a year earlier, with the FY2024 full-year figure at -$3.2 million, down 202.55% from the prior year.
- Non Operating Investment Income slipped to -$1.9 million in Q2 2024 per HROW's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $4.8 million in Q4 2020 and bottomed at -$10.8 million in Q1 2020.
- The 5-year median for Non Operating Investment Income is -$893500.0 (2020), against an average of -$1.1 million.
- Across the five-year window, Non Operating Investment Income slumped 4365.02% in 2020 and jumped 1369.06% in 2023, its largest moves.
- Year by year, Non Operating Investment Income stood at $4.8 million in 2020, then tumbled by 131.04% to -$1.5 million in 2021, then jumped by 195.97% to $1.4 million in 2022, then sank by 70.85% to $416000.0 in 2023, then tumbled by 562.26% to -$1.9 million in 2024.
- Per Business Quant, the three latest HROW Non Operating Investment Income figures stand at -$1.9 million (Q2 2024), -$1.2 million (Q1 2024), and $416000.0 (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.91 Bn | 88.04 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.05 Bn | 20.89 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Harrow | 1.42 Bn | 1.32 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1.92 Mn |
| Jun 30, 2024 | -1.92 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Dec 31, 2023 | 416,000.00 |
| Dec 31, 2023 | 416,000.00 |
| Sep 30, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | -714,000.00 |
| Jun 30, 2023 | -714,000.00 |
| Mar 31, 2023 | 2.04 Mn |
| Mar 31, 2023 | 2.04 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | 139,000.00 |
| Mar 31, 2022 | 139,000.00 |